Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Phase 1NBIP-1968Positive

AI Analysis

Summary

Neurocrine Biosciences announced initiation of a Phase 1 first-in-human clinical study of NBIP-1968, a GLP-1/GIP/Glucagon receptor triple agonist for obesity and metabolic disease. The study represents an important milestone in advancing Neurocrine's metabolic disease pipeline.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.60

Phase 1first-in-humanGLP-1 agonistobesitymetabolic diseasetriple agonist

Related Companies

$NBIX

Read the original article

Published by PR Newswire Pharma on August 7, 2026 12:30 PM

Read Original